Gilead, the world’s largest developer of HIV medications, has for some time highlighted lenacapavir as one of its most important experimental programs. The drug has a unique way of preventing HIV from replicating. And, if approved, it would be the only treatment given every six months, which is much less often than currently available options.
As such, Wall Street came to have high expectations for lenacapavir. According to the investment bank Mizuho Securities, the consensus among analysts has been that sales from the drug could exceed $1.1 billion by 2030.
